Exact Sciences Corporation (EXAS): Price and Financial Metrics

Exact Sciences Corporation (EXAS): $130.97

3.03 (+2.37%)

POWR Rating

Component Grades














  • EXAS scores best on the Sentiment dimension, with a Sentiment rank ahead of 76.07% of US stocks.
  • The strongest trend for EXAS is in Stability, which has been heading up over the past 31 weeks.
  • EXAS ranks lowest in Growth; there it ranks in the 6th percentile.

EXAS Stock Summary

  • With a market capitalization of $21,900,155,979, Exact Sciences Corp has a greater market value than 89.17% of US stocks.
  • Price to trailing twelve month operating cash flow for EXAS is currently 200.77, higher than 97.98% of US stocks with positive operating cash flow.
  • In terms of twelve month growth in earnings before interest and taxes, Exact Sciences Corp is reporting a growth rate of 315.9%; that's higher than 93.88% of US stocks.
  • Stocks that are quantitatively similar to EXAS, based on their financial statements, market capitalization, and price volatility, are ALNY, TXG, NTRA, TTWO, and CHKP.
  • EXAS's SEC filings can be seen here. And to visit Exact Sciences Corp's official web site, go to www.exactsciences.com.

EXAS Price Target

For more insight on analysts targets of EXAS, see our EXAS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $156.89 Average Broker Recommendation 1.34 (Strong Buy)

EXAS Stock Price Chart Interactive Chart >

Price chart for EXAS

EXAS Price/Volume Stats

Current price $130.97 52-week high $159.54
Prev. close $127.94 52-week low $70.75
Day low $127.50 Volume 1,194,600
Day high $131.66 Avg. volume 1,654,512
50-day MA $116.79 Dividend yield N/A
200-day MA $121.84 Market Cap 22.47B

Exact Sciences Corporation (EXAS) Company Bio

Exact Sciences is a molecular diagnostics company focused on gastrointestinal cancers. The company develops the Cologuard, a non-invasive stool-based DNA colorectal cancer screening test that is designed to detect pre-cancerous lesions or polyps, and each of the four stages of colorectal cancer. The company was founded in 1995 and is based in Madison, Wisconsin.

EXAS Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$130.97$0 -100%

Below please find a table outlining a discounted cash flow forecast for EXAS, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Exact Sciences Corp ranked in the 0th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 100%. As for the metrics that stood out in our discounted cash flow analysis of Exact Sciences Corp, consider:

  • Its compound free cash flow growth rate, as measured over the past 0.21 years, is -0.9% -- higher than just 0.42% of stocks in our DCF forecasting set.
  • Exact Sciences Corp's interest coverage rate -- a measure of gross earnings relative to interest payments -- comes in at -12.57. This coverage rate is greater than that of only 5.95% of stocks we're observing for the purpose of forecasting via discounted cash flows.
  • As a business, Exact Sciences Corp experienced a tax rate of about 21% over the past twelve months; relative to its sector (Healthcare), this tax rate is higher than 86.3% of stocks generating free cash flow.

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as EXAS, try AGHC, AMYT, CRY, CSTL, and EDAP.

EXAS Latest News Stream

Event/Time News Detail
Loading, please wait...

EXAS Latest Social Stream

Loading social stream, please wait...

View Full EXAS Social Stream

Latest EXAS News From Around the Web

Below are the latest news stories about Exact Sciences Corp that investors may wish to consider to help them evaluate EXAS as an investment opportunity.

Exact Sciences Technical Correction Is Now Behind Us

Jim Cramer sees the upside in the company but the charts suggest further weakness is possible. Prices are trading below the declining 50-day moving average line and below the cresting 200-day line. The On-Balance-Volume (OBV) line followed the price action lower and made an early May low.

Yahoo | June 8, 2021

Thursdays Top Analyst Upgrades and Downgrades: Allstate, EOG Resources, Exact Sciences, Occidental Petroleum, SolarEdge, Sunrun, Take-Two, Tilray and More

No summary available.

24/7 Wall street | June 3, 2021

Exact Sciences (EXAS) Down 1.4% Since Last Earnings Report: Can It Rebound?

Exact Sciences (EXAS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Yahoo | June 3, 2021

Cathie Woods ARK ETF raises stake in Exact Sciences

No summary available.

Seeking Alpha | June 1, 2021

Here's Why You Should Hold on to Exact Sciences (EXAS) Stock

Investors are optimistic about Exact Sciences (EXAS) on solid first-quarter performance and strategic partnerships.

Yahoo | May 26, 2021

Read More 'EXAS' Stories Here

EXAS Price Returns

1-mo 19.19%
3-mo 3.94%
6-mo N/A
1-year 58.64%
3-year 105.06%
5-year 1,034.92%
YTD -1.15%
2020 43.26%
2019 46.56%
2018 20.10%
2017 293.26%
2016 44.75%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.9107 seconds.